J.M. Läuffer

784 total citations
21 papers, 573 citations indexed

About

J.M. Läuffer is a scholar working on Surgery, Epidemiology and Oncology. According to data from OpenAlex, J.M. Läuffer has authored 21 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 6 papers in Epidemiology and 5 papers in Oncology. Recurrent topics in J.M. Läuffer's work include Hepatitis C virus research (4 papers), Cardiovascular, Neuropeptides, and Oxidative Stress Research (3 papers) and Neuroendocrine Tumor Research Advances (3 papers). J.M. Läuffer is often cited by papers focused on Hepatitis C virus research (4 papers), Cardiovascular, Neuropeptides, and Oxidative Stress Research (3 papers) and Neuroendocrine Tumor Research Advances (3 papers). J.M. Läuffer collaborates with scholars based in Switzerland, United States and Germany. J.M. Läuffer's co-authors include Hans U. Baer, L. Krähenbühl, Arthur Zimmermann, Jürgen Triller, Laura H. Tang, Irvin M. Modlin, Christoph A. Maurer, M.W. Büchler, C. Stoupis and K Käch and has published in prestigious journals such as Gastroenterology, Cancer and Journal of Bone and Joint Surgery.

In The Last Decade

J.M. Läuffer

20 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.M. Läuffer Switzerland 13 279 199 127 100 87 21 573
Ramsès Wassef Canada 14 228 0.8× 115 0.6× 92 0.7× 44 0.4× 18 0.2× 31 610
T Kishimoto Japan 9 166 0.6× 159 0.8× 68 0.5× 93 0.9× 18 0.2× 15 710
Masamitsu Unakami Japan 10 205 0.7× 75 0.4× 220 1.7× 119 1.2× 42 0.5× 29 562
S Kröber Germany 11 78 0.3× 119 0.6× 223 1.8× 60 0.6× 8 0.1× 22 604
Christoph Wahl Switzerland 5 84 0.3× 36 0.2× 115 0.9× 62 0.6× 36 0.4× 7 431
S. Oleesky United Kingdom 11 242 0.9× 92 0.5× 137 1.1× 109 1.1× 47 0.5× 17 703
David R. Herbold United States 14 147 0.5× 101 0.5× 69 0.5× 171 1.7× 29 0.3× 23 512
R. R. Bollinger United States 12 631 2.3× 34 0.2× 66 0.5× 87 0.9× 94 1.1× 46 949
Shingo Okamoto Japan 10 266 1.0× 37 0.2× 79 0.6× 35 0.3× 17 0.2× 22 500
Philip Cohen United States 14 276 1.0× 48 0.2× 54 0.4× 77 0.8× 42 0.5× 23 545

Countries citing papers authored by J.M. Läuffer

Since Specialization
Citations

This map shows the geographic impact of J.M. Läuffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.M. Läuffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.M. Läuffer more than expected).

Fields of papers citing papers by J.M. Läuffer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.M. Läuffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.M. Läuffer. The network helps show where J.M. Läuffer may publish in the future.

Co-authorship network of co-authors of J.M. Läuffer

This figure shows the co-authorship network connecting the top 25 collaborators of J.M. Läuffer. A scholar is included among the top collaborators of J.M. Läuffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.M. Läuffer. J.M. Läuffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colombo, M., Inmaculada Fernández, Paulo Roberto Abrão Ferreira, et al.. (2013). Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut. 63(7). 1150–1158. 42 indexed citations
2.
Colombo, Massimo, Simone I. Strasser, Petr Urbánek, et al.. (2013). 806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION. Journal of Hepatology. 58. S329–S330. 5 indexed citations
3.
Colombo, M., A. Picciotto, Pietro Andreoné, et al.. (2013). OC-26 Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the Italian telaprevir early access program. Digestive and Liver Disease. 45. S9–S9.
4.
Kresken, Michael, et al.. (2011). In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time–kill methodology. International Journal of Antimicrobial Agents. 38(1). 70–75. 20 indexed citations
5.
6.
Quervain, Inès A. Kramers‐de, J.M. Läuffer, K Käch, O. Trentz, & E. Stüssi. (2001). Functional Donor-Site Morbidity During Level and Uphill Gait After a Gastrocnemius or Soleus Muscle-Flap Procedure. Journal of Bone and Joint Surgery. 83(2). 239–246. 48 indexed citations
7.
Läuffer, J.M., Laura H. Tang, Tong Zhang, et al.. (2001). PACAP mediates the neural proliferative pathway of Mastomys Enterochromaffin-like cell transformation. Regulatory Peptides. 102(2-3). 157–164. 22 indexed citations
8.
9.
Läuffer, J.M., Christoph A. Maurer, Hans‐Peter Marti, et al.. (1999). Transarterial chemoembolization for hepatocellular carcinoma arising in a hepatitis C virus-seropositive renal allograft recipient. Transplantation Proceedings. 31(3). 1710–1712. 1 indexed citations
10.
Läuffer, J.M., et al.. (1999). Multidisciplinary Approach to Palliation of Obstructive Jaundice Caused by a Central Hepatocellular Carcinoma. Digestive Surgery. 16(6). 531–536. 8 indexed citations
11.
Läuffer, J.M., Irvin M. Modlin, Toshinori Hinoue, et al.. (1999). Pituitary adenylate cyclase-activating polypeptide modulates gastric enterochromaffin-like cell proliferation in rats. Gastroenterology. 116(3). 623–635. 34 indexed citations
12.
Läuffer, J.M., Hans U. Baer, Christoph A. Maurer, et al.. (1999). Intrapancreatic Accessory Spleen: A Rare Cause of a Pancreatic Mass. International Journal of Gastrointestinal Cancer. 25(1). 65–68. 36 indexed citations
13.
Läuffer, J.M., Irvin M. Modlin, & Laura H. Tang. (1999). Biological relevance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the gastrointestinal tract. Regulatory Peptides. 84(1-3). 1–12. 55 indexed citations
14.
Läuffer, J.M., et al.. (1998). Biliary cystadenocarcinoma of the liver: the need for complete resection. European Journal of Cancer. 34(12). 1845–1851. 64 indexed citations
15.
Maurer, Christoph A., Markus Borner, J.M. Läuffer, et al.. (1998). Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. International Journal of Pancreatology. 23(3). 181–186. 25 indexed citations
16.
Läuffer, J.M., et al.. (1998). Case Report: Adenomyoma of the Distal Common Bile Duct Mimicking Cholangiocarcinoma. Digestive Diseases and Sciences. 43(6). 1200–1204. 17 indexed citations
17.
Läuffer, J.M., et al.. (1998). Pituitary adenylate cyclase-activating peptide (PACAP) modulates gastric enterochromaffin-like (ECL) cell proliferation in rats. Gastroenterology. 114. A1158–A1158. 3 indexed citations
18.
Läuffer, J.M., et al.. (1997). Hepatocellular Carcinoma and Hepatoid Adenocarcinoma of the Stomach. Digestive Surgery. 14(6). 557–561. 1 indexed citations
19.
Baer, Hans U., et al.. (1997). Radikale onkologische Chirurgie als Therapieprinzip beim Pankreaskarzinom. European surgery. Supplement/European surgery. 29(5). 267–270. 1 indexed citations
20.
Läuffer, J.M., Arthur Zimmermann, L. Krähenbühl, Jürgen Triller, & Hans U. Baer. (1996). Epithelioid hemangioendothelioma of the liver: A rare hepatic tumor. Cancer. 78(11). 2318–2327. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ramsès Wassef Breakdown of academic impact, for papers by T Kishimoto Breakdown of academic impact, for papers by Masamitsu Unakami Breakdown of academic impact, for papers by S Kröber Breakdown of academic impact, for papers by Christoph Wahl Breakdown of academic impact, for papers by S. Oleesky Breakdown of academic impact, for papers by David R. Herbold Breakdown of academic impact, for papers by R. R. Bollinger Breakdown of academic impact, for papers by Shingo Okamoto Breakdown of academic impact, for papers by Philip Cohen
Rankless by CCL
2026